Tribe Technologies
Trending >

Supreme Pharmaceuticals is undervalued, says Canaccord Genuity

Supreme Cannabis

Supreme CannabisIt doesn’t yet have a sales license, but Supreme Pharmaceuticals (Supreme Pharmaceuticals Stock Quote, Chart, News: TSXV:FIRE) is making real progress, says Canaccord Genuity analyst Matt Bottomley.

This morning, Supreme Pharamaceuticals announced it had received several updates from Health Canada regarding its cultivation licence pursuant to the access to cannabis for medical purposes regulations. Management said Health Canada was in the process of testing its dried cannabis samples and has removed the previous production and storage capacity of the licence, allowing Supreme to store up to $150-million worth of cannabis at any given time.

“We are pleased to be making progress with Health Canada,” said CEO John Fowler. “The forthcoming approval to sell cannabis genetics is one leg of our B2B sales model, allowing us to monetize our genetic inventory. As we await an update on the sales approval, we continue to cultivate and build our inventory in advance of sales approval.”

Bottomley says a sales license for Supreme could be just around the corner, and thinks there are a number of recent positives.

“Although a lack of sales license continues to represent a significant overhang, we consider this update an incremental positive indicator, along with Health Canada’s recent announcement that it will be adding more resources to streamline the ACMPR application process,” the analyst says. “We believe Supreme’s current valuation is attractive ahead of this potential major near-term catalyst, and we would remain buyers at current trading levels.”

In a research update to clients today, Bottomley maintained his “Speculative Buy” rating and one-year price target of $2.10 on Supreme Pharmaceuticals, implying a return of 60.3 per cent at the time of publication.

Bottomley thinks Supreme will post EBITDA of negative $5.4-million on revenue of zero in 2017. He expects those numbers will improve to EBITDA of positive $3.8-million on a topline of $22-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook


Leave a Reply